Your browser is no longer supported. Please, upgrade your browser.
CNAT Conatus Pharmaceuticals Inc. monthly Stock Chart
CNAT [NASD]
Conatus Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.31 Insider Own2.80% Shs Outstand33.17M Perf Week-13.80%
Market Cap184.43M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float32.34M Perf Month62.53%
Income- PEG- EPS next Q- Inst Own13.92% Short Float0.40% Perf Quarter35.48%
Sales14.69M P/S12.55 EPS this Y- Inst Trans- Short Ratio0.93 Perf Half Y67.98%
Book/sh0.53 P/B10.45 EPS next Y- ROA- Target Price- Perf Year-33.41%
Cash/sh- P/C- EPS next 5Y38.00% ROE- 52W Range2.30 - 10.70 Perf YTD39.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.04% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low141.42% ATR0.84
Employees5 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)59.75 Volatility25.00% 18.86%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.20 Prev Close5.56
ShortableNo LT Debt/Eq- EarningsJun 10 AMC Payout- Avg Volume140.72K Price5.56
Recom3.00 SMA2013.49% SMA5046.15% SMA20050.04% Volume0 Change0.00%
Dec-06-18Downgrade Stifel Buy → Hold
Feb-08-18Initiated ROTH Capital Buy $20
Nov-02-17Reiterated H.C. Wainwright Buy $18 → $17
Mar-16-17Reiterated Stifel Buy $7 → $9
Dec-20-16Reiterated Stifel Buy $5 → $7
Dec-20-16Reiterated H.C. Wainwright Buy $9 → $18
Nov-09-16Reiterated Stifel Buy $6 → $5
Jul-01-16Resumed ROTH Capital Buy
Nov-05-15Reiterated Stifel Buy $11 → $9
Sep-22-15Initiated H.C. Wainwright Buy $15
Apr-28-15Initiated Brean Capital Buy $13
Mar-17-15Resumed ROTH Capital Buy $15
Mar-12-15Reiterated Stifel Buy $13 → $11
Jan-09-15Reiterated ROTH Capital Buy $19 → $12
Oct-21-14Initiated MLV & Co Buy $16
Aug-14-14Reiterated Stifel Buy $14 → $13
Aug-19-13Initiated Stifel Buy $16
May-18-20 08:00AM  
May-14-20 08:00AM  
May-11-20 08:00AM  
May-07-20 04:05PM  
May-01-20 04:05PM  
Apr-20-20 08:00AM  
Apr-15-20 08:00AM  
Apr-06-20 08:00AM  
Mar-11-20 04:45PM  
Feb-06-20 08:00AM  
Jan-28-20 04:05PM  
Dec-02-19 09:04AM  
Nov-29-19 08:41AM  
Nov-18-19 04:05PM  
Nov-05-19 07:15PM  
04:05PM  
Nov-03-19 08:22AM  
Oct-31-19 10:35AM  
Oct-11-19 12:02PM  
09:59AM  
Sep-19-19 10:29AM  
Sep-10-19 09:21AM  
Aug-19-19 09:00AM  
Aug-07-19 11:00AM  
Aug-06-19 07:25PM  
04:05PM  
Jul-31-19 10:36AM  
Jul-25-19 01:46PM  
Jun-26-19 04:17PM  
08:37AM  
07:19AM  
06:07AM  
Jun-25-19 11:32AM  
Jun-24-19 05:00PM  
04:19PM  
04:06PM  
04:05PM  
Jun-12-19 06:27PM  
Jun-01-19 09:31AM  
May-28-19 11:48AM  
May-24-19 09:39AM  
May-06-19 02:53PM  
May-02-19 07:15PM  
06:11PM  
Apr-30-19 07:30AM  
Apr-24-19 10:33AM  
Apr-15-19 07:30AM  
Apr-07-19 05:04PM  
09:30AM  
Apr-02-19 07:30AM  
Mar-27-19 10:55AM  
Mar-22-19 05:43PM  
10:49AM  
Mar-21-19 04:05PM  
Mar-20-19 11:10AM  
Mar-14-19 06:09PM  
Mar-13-19 10:35AM  
09:00AM  
Mar-11-19 10:57AM  
Mar-08-19 04:05PM  
Mar-01-19 07:30AM  
Feb-25-19 01:20PM  
Feb-13-19 03:36PM  
Feb-12-19 07:30AM  
Jan-30-19 08:05AM  
Jan-29-19 10:05AM  
Jan-28-19 07:30AM  
Dec-28-18 05:40PM  
Dec-13-18 09:26AM  
Dec-12-18 10:03AM  
Dec-07-18 08:04AM  
Dec-06-18 02:51PM  
02:13PM  
07:00AM  
Dec-05-18 07:30AM  
Nov-16-18 10:42AM  
07:50AM  
Nov-14-18 08:46AM  
Nov-09-18 05:28PM  
Nov-08-18 07:30AM  
Nov-05-18 07:00AM  
Nov-02-18 12:30PM  
07:30AM  
05:03AM  
Nov-01-18 04:05PM  
Oct-25-18 07:30AM  
Oct-11-18 08:51AM  
Oct-02-18 04:05PM  
Sep-25-18 08:00AM  
Sep-20-18 07:30AM  
Sep-19-18 08:00AM  
07:30AM  
Sep-18-18 10:50AM  
Aug-31-18 09:58AM  
09:49AM  
Aug-29-18 07:30AM  
Aug-23-18 08:00AM  
Aug-03-18 05:14PM  
Aug-02-18 11:47AM  
Aug-01-18 08:20PM  
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Marshall Keith WEVP, COO & CFOMay 22Option Exercise0.0038,500038,500May 27 06:09 AM
Mento Steven JDirectorMay 22Option Exercise0.0065,000071,000May 27 06:04 AM
Spada Alfred P.EVP, R&D and CSOMay 22Option Exercise0.0031,343032,555May 27 06:05 AM